Tuesday, Boston Scientific Corporation (NYSE:BSX) agreed to acquire Silk Road Medical Inc (NASDAQ:SILK) for $27.50 in cash per share, representing an equity value of approximately $1.26 billion. The per-share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical’s common stock over the past 60 days. Related: Heart Devices Focused Silk Road Medical Stock Gets an Upgrade – Analyst Says New CEO’s Initiatives Sets Stage For ‘Back On Track’ Silk Road Medical is a minimally invasive medical device company for carotid artery procedures. The acquisition adds technology for stroke prevention to Boston Scientific’s vascular portfolio. The ...